NRC Proposes Draft Radiation Guide Affecting Novartis' Pluvicto Treatment
What happened
The Nuclear Regulatory Commission proposed a draft radiation guide, DG-8070, which revises the rules for releasing patients who receive radioactive medicines. The draft sets a default limit of 41 GBq for a lutetium-177 patient, assuming a caregiver stays within three feet 100% of the time. Pluvicto, which is administered in up to six doses totaling 44.4 GBq, slightly exceeds this proposed threshold. The current guidance assumes only 25% caregiver presence.
From medicaldaily.com
Why it matters
Nuclear medicine groups warn that if the draft guide is finalized, patients receiving Pluvicto could face longer clinic stays, hospital admissions, or longer drives. Furthermore, doctors and drugmakers told regulators that the new standard could lead smaller treatment sites to stop offering the therapy.
From medicaldaily.com
Who's involved
- Nuclear Regulatory CommissionGovernment agency proposing the draft radiation guide
- NovartisPharmaceutical company that manufactures Pluvicto
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Nuclear Regulatory Commission
government agency of the United States
-
Novartis
Swiss-American multinational pharmaceutical corporation
Related events
- The Nuclear Regulatory Commission (NRC) regulates civilian nuclear energy technologies.
- Executive Order 14300 revises radiation standards in Idaho.
- A report has been released supporting the assessment of risks associated with nuclear projects.
- The nuclear industry is pushing to discard decades-old safety measures, backed by presidential pressure on the NRC.